Literature DB >> 22172947

Cooperation between ARID3A and p53 in the transcriptional activation of p21WAF1 in response to DNA damage.

Widya Lestari1, Solachuddin J A Ichwan, Megumi Otsu, Shumpei Yamada, Sachiko Iseki, Shihoko Shimizu, Masa-Aki Ikeda.   

Abstract

ARID3A/DRIL1/Bright is a family member of the AT rich interaction domain (ARID) DNA-binding proteins that are involved in diverse biological processes. We have reported that p53 activates ARID3A transcription, and ARID3A overexpression induces G1 arrest. However, the role of ARID3A in the p53 pathway remains unclear. Here, we show that ARID3A cooperates with p53 to transcriptionally activate p21(WAF1), a p53-target gene important for cell-cycle arrest. ARID3A bound to its binding sites in the p21(WAF1) promoter in vivo and in vitro, and induced p21(WAF1) transcription in U2OS cells expressing wild-type p53 but not Saos-2 cells lacking p53. The co-expression of ARID3A with p53 cooperates to activate p21(WAF1) transcription and the stably transfected p21(WAF1) promoter. Mutation of the ARID3A binding sites reduced the p21(WAF1) promoter activity, and siRNA-based ARID3A knockdown suppressed the transcription of p21(WAF1), but not the proapoptotic NOXA and PUMA in response to DNA damage. Furthermore, p53 knockdown decreased ARID3A transcription, and, conversely, ARID3A overexpression and knockdown resulted in an increase or decrease in p53 stability, respectively. These results indicate both cooperative and interdependent roles for ARID3A and p53 in the transcriptional activation of p21(WAF1) in response to DNA damage.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22172947     DOI: 10.1016/j.bbrc.2011.12.003

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

Review 1.  The Bright Side of Hematopoiesis: Regulatory Roles of ARID3a/Bright in Human and Mouse Hematopoiesis.

Authors:  Michelle L Ratliff; Troy D Templeton; Julie M Ward; Carol F Webb
Journal:  Front Immunol       Date:  2014-03-19       Impact factor: 7.561

Review 2.  Recent advances in the ARID family: focusing on roles in human cancer.

Authors:  Chen Lin; Wei Song; Xinyu Bi; Jianjun Zhao; Zhen Huang; Zhiyu Li; Jianguo Zhou; Jianqiang Cai; Hong Zhao
Journal:  Onco Targets Ther       Date:  2014-02-18       Impact factor: 4.147

3.  Bright/Arid3A acts as a barrier to somatic cell reprogramming through direct regulation of Oct4, Sox2, and Nanog.

Authors:  Melissa Popowski; Troy D Templeton; Bum-Kyu Lee; Catherine Rhee; He Li; Cathrine Miner; Joseph D Dekker; Shari Orlanski; Yehudit Bergman; Vishwanath R Iyer; Carol F Webb; Haley Tucker
Journal:  Stem Cell Reports       Date:  2014-01-14       Impact factor: 7.765

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.